To determine whether NAT affects tumor target expression levels, MSIs of CEACAM5, TMPRSS4, COL17A1, CLDN18, and AQP5 were compared between patients who received NAT and those who did not receive NAT, as shown in Supplementary Figure S3. The gene discussed is CEACAM5; the disease is neoplasm.